News
Numerous advocacy organizations are sounding the alarm over a recent HHS notice that restricts access to federal benefits for ...
Healthcare providers are making cybersecurity progress, but serious vulnerabilities remain — especially when it comes to AI ...
Opinion
GLP-1s, Personalization, and Big Pharma Power Plays: What’s Really at Stake in the Eli Lilly LawsuitThis lawsuit may look like a business dispute on the surface. But underneath, it’s about something much more important: the right of patients to receive personalized, affordable care.
Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...
A bill introduced by Rep. Earl L. "Buddy" Carter would ban PBMs’ use of spread pricing in Medicaid, among other reforms.
Hospital M&A activity slowed quite a bit in the first half of 2025, with deal volume and transacted revenue falling sharply amid economic uncertainty and sweeping policy changes. While traditional ...
Sarepta’s Elevidys will remain on the market with a black box warning. But this gene therapy for Duchenne muscular dystrophy still faces commercial headwinds and analysts say the company has ...
The One Big Beautiful Bill Act has drawn criticism from healthcare groups for slashing Medicaid and ACA subsidies, but it contains a few provisions that could drive progress.
Digital health funding held steady in the first half of 2025, with AI-focused startups capturing the majority of capital and driving rapid adoption among providers. The digital health space also saw ...
The Trump administration's healthcare policy changes from the gutting of medical research grants to changes on the CDC vaccine board were the focus of the discussion on the latest episode of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results